abstract
- CSL 112 aims to evaluate the efficacy of the blood product on reducing the risk of MACE (CV death, MI, or stroke) from the time of randomization through 90 days in subjects diagnosed with STEMI or NSTEMI (heart attacks).
A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of CSL112 in Subjects with Acute Coronary Syndrome
Grant
Overview
date/time interval
- November 2020 - May 2022
awarded by
Affiliation
contributor
- Dennis Lynn Morris Principal Investigator